PMID- 33572326
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20211204
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 4
DP  - 2021 Feb 9
TI  - The Role of mTOR Signaling as a Therapeutic Target in Cancer.
LID - 10.3390/ijms22041743 [doi]
LID - 1743
AB  - The aim of this review was to summarize current available information about the 
      role of phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin 
      (mTOR) signaling in cancer as a potential target for new therapy options. The 
      mTOR and PI3K/AKT/mTORC1 (mTOR complex 1) signaling are critical for the 
      regulation of many fundamental cell processes including protein synthesis, cell 
      growth, metabolism, survival, catabolism, and autophagy, and deregulated mTOR 
      signaling is implicated in cancer, metabolic dysregulation, and the aging 
      process. In this review, we summarize the information about the structure and 
      function of the mTOR pathway and discuss the mechanisms of its deregulation in 
      human cancers including genetic alterations of PI3K/AKT/mTOR pathway components. 
      We also present recent data regarding the PI3K/AKT/mTOR inhibitors in clinical 
      studies and the treatment of cancer, as well the attendant problems of resistance 
      and adverse effects.
FAU - Popova, Nadezhda V
AU  - Popova NV
AD  - Laboratory of Receptor Cell Biology, Shemyakin-Ovchinnikov Institute of 
      Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, 
      117997 Moscow, Russia.
FAU - Jucker, Manfred
AU  - Jucker M
AUID- ORCID: 0000-0003-2176-6526
AD  - Institute of Biochemistry and Signal Transduction, University Medical Center 
      Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210209
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (AKT1 protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Autophagy/drug effects/genetics
MH  - Cell Proliferation/drug effects/genetics
MH  - Clinical Trials as Topic
MH  - Drug Resistance, Neoplasm/genetics
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1/*metabolism
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasms/*drug therapy/genetics/pathology
MH  - Phosphatidylinositol 3-Kinase/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Kinase Inhibitors/*pharmacology/therapeutic use
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/genetics/metabolism
MH  - Signal Transduction/drug effects/genetics
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/genetics/*metabolism
MH  - Treatment Outcome
PMC - PMC7916160
OTO - NOTNLM
OT  - AKT
OT  - PI3K
OT  - cancer
OT  - mTOR
OT  - mutation
OT  - therapy
COIS- The authors declare no conflict of interest.
EDAT- 2021/02/13 06:00
MHDA- 2021/09/07 06:00
PMCR- 2021/02/09
CRDT- 2021/02/12 01:01
PHST- 2021/01/10 00:00 [received]
PHST- 2021/01/30 00:00 [revised]
PHST- 2021/02/03 00:00 [accepted]
PHST- 2021/02/12 01:01 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2021/02/09 00:00 [pmc-release]
AID - ijms22041743 [pii]
AID - ijms-22-01743 [pii]
AID - 10.3390/ijms22041743 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Feb 9;22(4):1743. doi: 10.3390/ijms22041743.